Exelixis Stock Performance
| EXEL Stock | USD 36.46 0.53 1.48% |
On a scale of 0 to 100, Exelixis holds a performance score of 18. The firm shows a Beta (market volatility) of 0.54, which means possible diversification benefits within a given portfolio. As returns on the market increase, Exelixis' returns are expected to increase less than the market. However, during the bear market, the loss of holding Exelixis is expected to be smaller as well. Please check Exelixis' downside variance, day median price, and the relationship between the treynor ratio and kurtosis , to make a quick decision on whether Exelixis' price patterns will revert.
Risk-Adjusted Performance
18 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Exelixis are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. Despite quite weak technical and fundamental indicators, Exelixis disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.48 | Five Day Return 1.84 | Year To Date Return 52.36 | Ten Year Return 2.3 K | All Time Return 147.19 |
1 | Disposition of 25000 shares by Hessekiel Jeffrey of Exelixis at 26.38 subject to Rule 16b-3 | 09/23/2024 |
2 | Disposition of 480000 shares by Michael Morrissey of Exelixis at 24.41 subject to Rule 16b-3 | 10/01/2024 |
3 | Exelixis Q3 2024 Earnings Preview | 10/28/2024 |
4 | Exelixis Shows Rising Price Performance With Jump To 93 RS Rating | 10/31/2024 |
5 | Exelixis director George Poste sells 1.02 million in shares | 11/06/2024 |
6 | Disposition of 27224 shares by Peterson Amy C. of Exelixis at 35.05 subject to Rule 16b-3 | 11/15/2024 |
7 | Disposition of 19381 shares by Haley Patrick J. of Exelixis at 34.41 subject to Rule 16b-3 | 11/18/2024 |
8 | Phocas Financial Corp. Has 3.76 Million Stock Holdings in Exelixis, Inc. | 11/19/2024 |
9 | Exelixis exec Haley Patrick sells 1.43 million in stock | 11/20/2024 |
10 | 3 TSX Penny Stocks With Market Caps Over CA30M | 11/21/2024 |
11 | Disposition of 10000 shares by Haley Patrick J. of Exelixis at 35.27 subject to Rule 16b-3 | 11/22/2024 |
12 | Exelixis is a Top-Ranked Value Stock Should You Buy | 11/25/2024 |
13 | Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib for the Treatment of Patients with Previously Treated Advanced... | 11/26/2024 |
14 | Exelixis reiterates Equal Weight rating, stock target amid FDA update | 11/27/2024 |
15 | Techne Up 2.2 percent Since Last Earnings Report Can It Continue | 11/29/2024 |
| Begin Period Cash Flow | 502.7 M |
Exelixis |
Exelixis Relative Risk vs. Return Landscape
If you would invest 2,583 in Exelixis on September 1, 2024 and sell it today you would earn a total of 1,063 from holding Exelixis or generate 41.15% return on investment over 90 days. Exelixis is currently generating 0.5757% in daily expected returns and assumes 2.4002% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than Exelixis, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Exelixis Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Exelixis' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Exelixis, and traders can use it to determine the average amount a Exelixis' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2399
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | EXEL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.4 actual daily | 21 79% of assets are more volatile |
Expected Return
| 0.58 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.24 actual daily | 18 82% of assets perform better |
Based on monthly moving average Exelixis is performing at about 18% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Exelixis by adding it to a well-diversified portfolio.
Exelixis Fundamentals Growth
Exelixis Stock prices reflect investors' perceptions of the future prospects and financial health of Exelixis, and Exelixis fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Exelixis Stock performance.
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.35 % | ||||
| Current Valuation | 9.27 B | ||||
| Shares Outstanding | 285.58 M | ||||
| Price To Earning | 48.17 X | ||||
| Price To Book | 4.51 X | ||||
| Price To Sales | 5.00 X | ||||
| Revenue | 1.83 B | ||||
| Gross Profit | 1.55 B | ||||
| EBITDA | 196.6 M | ||||
| Net Income | 207.76 M | ||||
| Cash And Equivalents | 1.53 B | ||||
| Cash Per Share | 4.77 X | ||||
| Total Debt | 189.94 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 6.08 X | ||||
| Book Value Per Share | 7.96 X | ||||
| Cash Flow From Operations | 333.32 M | ||||
| Earnings Per Share | 1.55 X | ||||
| Market Capitalization | 10.41 B | ||||
| Total Asset | 2.94 B | ||||
| Retained Earnings | (173.35 M) | ||||
| Working Capital | 923.68 M | ||||
| Current Asset | 178.66 M | ||||
| Current Liabilities | 52.25 M | ||||
About Exelixis Performance
By examining Exelixis' fundamental ratios, stakeholders can obtain critical insights into Exelixis' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Exelixis is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 189.79 | 180.30 | |
| Return On Tangible Assets | 0.09 | 0.10 | |
| Return On Capital Employed | 0.13 | 0.13 | |
| Return On Assets | 0.09 | 0.09 | |
| Return On Equity | 0.10 | 0.10 |
Things to note about Exelixis performance evaluation
Checking the ongoing alerts about Exelixis for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Exelixis help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Exelixis has a strong financial position based on the latest SEC filings | |
| Over 89.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: Techne Up 2.2 percent Since Last Earnings Report Can It Continue |
- Analyzing Exelixis' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Exelixis' stock is overvalued or undervalued compared to its peers.
- Examining Exelixis' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Exelixis' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Exelixis' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Exelixis' stock. These opinions can provide insight into Exelixis' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 121.699 | Earnings Share 1.55 | Revenue Per Share 7.032 | Quarterly Revenue Growth 0.143 | Return On Assets 0.1281 |
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.